CCR2 and retinitis pigmentosa: The effects of KUS121, confirmed in CCR2-deficient mice, were consistent with our previous data addressing the compound's therapeutic efficacy on animal models of glaucoma and retinitis pigmentosa [13, 14, 15], indicating that KUSs may be useful in the treatment of RPE abnormalities and AMD, not only in glaucoma and retinitis pigmentosa.